Company news

Praxis Precision Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

April 5, 2023

Praxis Precision Medicines to Present at Upcoming Investor Conferences

March 2, 2023

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3

March 2, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 6, 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

December 12, 2022

Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting

November 27, 2022

Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies

November 27, 2022

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 8, 2022

Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference

September 20, 2022

Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing

September 19, 2022

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

September 19, 2022

Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs

September 6, 2022

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 7, 2022

Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

August 2, 2022

Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder

June 5, 2022

Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

May 22, 2022

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

May 8, 2022

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 8, 2022

Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference

May 3, 2022

Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022

May 1, 2022

Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day

April 26, 2022

Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022

April 12, 2022

Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting

March 31, 2022

Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day

March 20, 2022

Praxis Precision Medicines to Present at Cowen’s 42nd Annual Healthcare Conference

February 28, 2022

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

February 21, 2022

Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562

January 17, 2022

Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021

December 9, 2021

Praxis Precision Medicines Announces Management Team Appointments

December 1, 2021

Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting

November 28, 2021

Praxis Precision Medicines to Present at Piper Sandler’s 33rd Annual Virtual Healthcare Conference

November 23, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 2, 2021

Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, November 3, 2021

October 21, 2021

Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference

August 31, 2021

Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms

August 15, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 15, 2021

Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference

August 1, 2021

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

June 21, 2021

Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer

May 24, 2021

Praxis Precision Medicines Prices Public Offering of Common Stock

May 12, 2021

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results

May 10, 2021

Praxis Precision Medicines Announces Proposed Public Offering of Common Stock

May 10, 2021

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE

April 29, 2021

Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.

April 28, 2021

Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.

April 14, 2021

Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE

April 13, 2021

Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day

March 23, 2021

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

March 16, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 35 decks. Every deck is listed under its year.